Recent findings suggest that post-COVID chronic cough may be driven by neurological factors, not just respiratory issues.

Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total ...

Behavioral cough suppression therapy may be effective in patients with refractory and unexplained chronic cough (RCC and UCC).

There are no approved therapies for the treatment of chronic cough in IPF and current off-label treatment options provide minimal benefit to patients. Refractory chronic cough affects approximately ...

AURORA, CO / ACCESS Newswire / January 31, 2025 / Exxel Pharma ("Exxel" or the "Company"), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal ...

Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market First-in-human Phase 1/1b single/multiple dose study in ...

Exxel is initiating a first-in-human Phase 1/1b clinical study of EX937 for refractory chronic cough, a significant unmet medical need with no FDA-approved treatments. In preclinical studies ...

Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market First-in-human Phase 1/1b single/multiple dose study in ...